| Prev Close | 291.10 |
| Open | 294.36 |
| Day Low/High | 289.63 / 295.00 |
| 52 Wk Low/High | 165.23 / 299.21 |
| Volume | 1.34M |
| Avg Volume | 2.03M |
Vertex Pharmaceuticals Inc. (VRTX)
291.26
0.16
0.06
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 259.28M |
| Market Cap | 75.48B |
| EPS | 4.60 |
| P/E Ratio | 50.45 |
| Div & Yield | N.A. (N.A) |
Latest News
Jim Cramer: Oil Tanked, and We're in Uncharted Waters
Oil isn't really worthless and Amazon isn't the only retailer that will survive, but we are in a mixed up market thanks to Covid-19.
Vertex Pharmaceuticals Could See More Gains but Weaker Momentum Is a Risk
The pace of the rally in the drugmaker's shares is slowing, which is one reason to keep an eye on its stock.
Don't Underestimate Vertex Pharmaceuticals
Here's how the stock might surprise Wall Street.
Vertex Pharmaceuticals: The 'Endpoint' Is a Bullish Golden Cross
VRTX is poised for further upside price gains.
The Technical Profile of This Market Remains Positive
The indices are within striking distance of the July highs after moving into position for a possible strong finish to the year.
Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter
Straying from these names could land you in quicksand as the 4th quarter begins.
Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop
It is all about perception, and here are strong names to pick up on market weakness.
2 Trading Opportunities in Health Care
The potential of these setups on the weekly chart is rather good.
Trying the Long Side of Vertex's Stock Again
After pharmaceutical company breaks out, charts suggest now is the time to go back in.
Cramer: 2017 Was a Year of Resurrection and Revival
Look no further than the top 10 winners in the S&P 500 and you will see just what I mean.
Cramer: Trump Doesn't Deserve All the Credit for Stock Rally
Of stocks seeing the biggest gains since the presidential election, only a few owe their success to Trump.
Vertex Pharmaceuticals Could Be Headed Higher Once Again
Trade from the long side, but have a sell stop below $149 in case of a reversal.
Vertex Pharmaceuticals: Looking East, West and to the Quants
Let's examine VRTX's sharp decline today.
Another Day - Another Busy Slate of Earnings
Ford Motor Co. leads a list of notable earnings reports being released throughout the day on Wednesday
Closing Bell: Vertex Pharmaceuticals Up on String of Upgrades; Records for Wall Street
The Nasdaq and S&P 500 ended at records for the second day in a row.
Cramer: There Are Powerful Themes in Several Bull Markets
It's a wonder to me how split this market really is.
Takeaways and Observations: Market Reversal
"The rally in the face of today's data (detailed by Peter Boockvar in the previous post) tells me how much machines and algos dominate trading: a mild winter goosed construction jobs service job data is so-so ISM services has just given back the ent...
Cramer: Stay the Course, but Keep Cash Handy
It's pretty normal to have profit-taking after such a strong first quarter.
Closing Bell: Barclays Bets on Alphabet Growth; Dow Falls, S&P 500 and Nasdaq Rise
A rally in crude oil gave rise to the energy sector in a mixed day of trading.
Vertex Pharmaceuticals Reaches Upside Price Target
Base building pays off.
What You Must Know About Cystic Fibrosis Drug CTP-656
Acquiring CTP-656 from Concert Pharmaceuticals will only cost Vertex around $250 million.
Activist Investors Shake Up the Boards at Tiffany & Bristol-Myers Squibb
Jana Partners are placing three members on Tiffany's board.
Vertex Pharmaceuticals to Rely on Acquisitions to Diversify Its Business
Vertex Pharmaceuticals will be weighing future acquisitions and partnerships to broaden is focus beyond cystic fibrosis.
Vertex Pharmaceuticals Sees Sales of Cystic Fibrosis Drug Lower Than Expected
Vertex Pharmaceuticals provided new financial guidance for 2017 on Sunday.
Here's What to Look for at the J.P. Morgan Healthcare Conference
The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.
Cramer: Reviewing S&P's Hit-and-Miss Parade
Even among the losers, buys are scarce.
